Truist Securities Reiterates Buy on Biogen, Lowers Price Target to $302
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Biogen (NASDAQ:BIIB) but lowered the price target from $340 to $302.
August 05, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has reiterated its Buy rating on Biogen but lowered the price target from $340 to $302.
The reiteration of the Buy rating is positive, but the lowered price target may temper investor enthusiasm. Overall, the impact is neutral as the positive rating balances the lower target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100